Metraipolis › archive › dc_509fb2bafed9

Apremilast attenuates hepatic steatosis and metabolic dysfunction in a murine model of MASLD: Implications for patients with Psoriatic disease — Europe PMC PMID:41232356

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41232356
DOI
10.1016/j.biopha.2025.118757
License (as archived)
solo-consultazione
Archived
2026-11-08T15:46:18.375Z
SHA-256 of the archived text
a5a09ea7f187ed9229a92916b272c773a7c2318f82dcd5d76f38e533188b3729
Stable URL of this page
https://metraipolis.com/documento/dc_509fb2bafed9

How to cite

Apremilast attenuates hepatic steatosis and metabolic dysfunction in a murine model of MASLD: Implications for patients with Psoriatic disease — Europe PMC PMID:41232356 — Europe PMC (en), https://europepmc.org/article/MED/41232356 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_509fb2bafed9 (Metraipolis archive dc_509fb2bafed9, sha256 a5a09ea7f187ed9229a92916b272c773a7c2318f82dcd5d76f38e533188b3729)
BibTeX
@misc{dc509fb2bafed9,
  title = {Apremilast attenuates hepatic steatosis and metabolic dysfunction in a murine model of MASLD: Implications for patients with Psoriatic disease — Europe PMC PMID:41232356},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41232356},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_509fb2bafed9; sha256 a5a09ea7f187ed9229a92916b272c773a7c2318f82dcd5d76f38e533188b3729},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41232356. Agents can read the archived copy with the MCP tool read_document.